| MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb C Xiao, DP Calado, G Galler, TH Thai, HC Patterson, J Wang, N Rajewsky, ... Cell 131 (1), 146-159, 2007 | 1319 | 2007 |
| Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage SB Koralov, SA Muljo, GR Galler, A Krek, T Chakraborty, C Kanellopoulou, ... Cell 132 (5), 860-874, 2008 | 717 | 2008 |
| HIV-1 Nef mimics an integrin receptor signal that recruits the polycomb group protein Eed to the plasma membrane V Witte, B Laffert, O Rosorius, P Lischka, K Blume, G Galler, A Stilper, ... Molecular cell 13 (2), 179-190, 2004 | 109 | 2004 |
| The pre‐B‐cell receptor induces silencing of VpreB and λ5 transcription MJ Parker, S Licence, L Erlandsson, GR Galler, L Chakalova, ... The EMBO journal 24 (22), 3895-3905, 2005 | 93 | 2005 |
| Surface μ heavy chain signals down-regulation of the V (D) J-recombinase machinery in the absence of surrogate light chain components GR Galler, C Mundt, M Parker, R Pelanda, IL Mårtensson, TH Winkler The Journal of experimental medicine 199 (11), 1523-1532, 2004 | 89 | 2004 |
| CD4+ and CD8a+ PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models LK Kristensen, C Fröhlich, C Christensen, MC Melander, TT Poulsen, ... Theranostics 9 (26), 8221, 2019 | 73 | 2019 |
| Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform T Gjetting, M Gad, C Fröhlich, T Lindsted, MC Melander, VK Bhatia, ... MAbs 11 (4), 666-680, 2019 | 27 | 2019 |
| Simultaneous targeting of two distinct epitopes on MET effectively inhibits MET-and HGF-driven tumor growth by multiple mechanisms MM Grandal, S Havrylov, TT Poulsen, K Koefoed, A Dahlman, GR Galler, ... Molecular cancer therapeutics 16 (12), 2780-2791, 2017 | 25 | 2017 |
| Anti-PD-1 antibodies and compositions G Galler, M Gad, K Koefoed, ID Horak, T Bouquin, M Kragh, M Pedersen US Patent 11,034,765, 2021 | 6 | 2021 |
| CD4 (+) and CD8a (+) PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models. Theranostics. 2019; 9: 8221–38 LK Kristensen, C Fröhlich, C Christensen, M Melander, T Poulsen, ... DOI: https://doi. org/10.7150/thno 37513, 8221-8238, 0 | 6 | |
| Anti-PD-1 antibodies and compositions J Lantto, T Bouquin, K Koefoed, T Gjetting, VK Bhatia, M Gad, GR Galler, ... US Patent 11,359,018, 2022 | 4 | 2022 |
| Anti-LAG-3 antibodies and compositions MM Grandal, VK Bhatia, T Gjetting, C Fröhlich, GR Galler, M Kragh, ... US Patent 11,390,676, 2022 | 3 | 2022 |
| Anti-lag-3 antibodies and compositions MM Grandal, VK BHATIA, T Gjetting, C Fröhlich, GR GALLER, M Kragh, ... | 3 | 2018 |
| Anti-PD-1 antibodies and compositions G Galler, M Gad, K Koefoed, ID Horak, T Bouquin, M Kragh, M Pedersen US Patent 12,030,942, 2024 | 1 | 2024 |
| Anti-tim-3 antibodies and compositions T Lindsted, T Gjetting, GR Galler, M Gad, MM Grandal, K Koefoed, ... US Patent App. 17/741,967, 2023 | 1 | 2023 |
| Anti-TIM-3 antibodies and compositions T Lindsted, T Gjetting, GR Galler, M Gad, MM Grandal, K Koefoed, ... US Patent 11,390,674, 2022 | 1 | 2022 |
| Pre-B-cell Receptor Mediated Regulation of the V (D) J-recombination Machinery in Murine B-lymphopoiesis GR Galler | 1 | 2004 |
| Anti-TIM-3 antibodies and compositions T Bouquin, GAD Monika, GR Galler, T Gjetting, MM Grandal, ID Horak, ... AU Patent App. 2,017,251,250 A, 2024 | | 2024 |
| Anti-lag-3 antibodies and compositions MM Grandal, VK Bhatia, T Gjetting, C Fröhlich, GR Galler, M Kragh, ... US Patent App. 18/490,500, 2024 | | 2024 |
| Anti-lag-3 antibodies and compositions MM Grandal, VK Bhatia, T Gjetting, C Fröhlich, GR Galler, M Kragh, ... US Patent 11,834,503, 2023 | | 2023 |
